SIRs and AERs for CHF (IRR)
| . | Observed, n . | Expected, n . | SIR . | 95% CI . | AER* . | AER, %/y . |
|---|---|---|---|---|---|---|
| Entire cohort | 88 | 19.29 | 4.46 | 3.58-5.47 | 95.5 | 0.96% |
| By sex | ||||||
| Male | 36 | 12.05 | 2.90 | 2.04-4.00 | 57.89 | 0.58% |
| Female | 52 | 7.24 | 7.05 | 5.29-9.16 | 146.38 | 1.46% |
| By age, y | ||||||
| <35 | 16 | 0.69 | 17.50 | 9.37-29.36 | 68.32 | 0.68% |
| 35–44 | 21 | 2.05 | 10.21 | 6.44-15.23 | 104.74 | 1.05% |
| 45–54 | 27 | 6.33 | 4.26 | 2.85-6.08 | 104.39 | 1.04% |
| 55+ | 26 | 10.21 | 2.55 | 1.69-3.65 | 135.66 | 1.36% |
| By diagnosis | ||||||
| Nonlymphoma | 22 | 7.54 | 2.91 | 1.86-4.31 | 66.64 | 0.67% |
| Lymphoma | 66 | 11.74 | 5.45 | 4.22-6.90 | 107.82 | 1.08% |
| . | Observed, n . | Expected, n . | SIR . | 95% CI . | AER* . | AER, %/y . |
|---|---|---|---|---|---|---|
| Entire cohort | 88 | 19.29 | 4.46 | 3.58-5.47 | 95.5 | 0.96% |
| By sex | ||||||
| Male | 36 | 12.05 | 2.90 | 2.04-4.00 | 57.89 | 0.58% |
| Female | 52 | 7.24 | 7.05 | 5.29-9.16 | 146.38 | 1.46% |
| By age, y | ||||||
| <35 | 16 | 0.69 | 17.50 | 9.37-29.36 | 68.32 | 0.68% |
| 35–44 | 21 | 2.05 | 10.21 | 6.44-15.23 | 104.74 | 1.05% |
| 45–54 | 27 | 6.33 | 4.26 | 2.85-6.08 | 104.39 | 1.04% |
| 55+ | 26 | 10.21 | 2.55 | 1.69-3.65 | 135.66 | 1.36% |
| By diagnosis | ||||||
| Nonlymphoma | 22 | 7.54 | 2.91 | 1.86-4.31 | 66.64 | 0.67% |
| Lymphoma | 66 | 11.74 | 5.45 | 4.22-6.90 | 107.82 | 1.08% |
Per 10 000 person-years.